Elisa Bergaggio

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 6

Top Topics

Advanced Non Small Cell Lung Cancer

Hydrogen Peroxide

Top Venues

Clinical and translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Elisa Bergaggio, Roberto Chiarle
Impact of ALK inhibitors to potentiate ALK.CAR-T therapy in neuroblastoma. Clinical and translational medicine 14 (6) (2024)
Elisa Bergaggio, Roberto Chiarle
Impact of ALK inhibitors to potentiate ALK.CAR-T therapy in neuroblastoma. Clinical and translational medicine 14 (6) (2024)
Elisa Bergaggio, Roberto Chiarle
Impact of ALK inhibitors to potentiate ALK.CAR-T therapy in neuroblastoma. Clinical and translational medicine 14 (6) (2024)
Ines Mota, Enrico Patrucco, Cristina Mastini, Navin R Mahadevan, Tran C Thai, Elisa Bergaggio, Taek-Chin Cheong, Giulia Leonardi, Elif Karaca-Atabay, Marco Campisi, Teresa Poggio, Matteo Menotti, Chiara Ambrogio, Dario Livio Longo, Susan Klaeger, Hasmik Keshishian, Zsófia M Sztupinszki, Zoltan Szallasi, Derin B Keskin, Jonathan S Duke-Cohan, Bruce Reinhold, Steven A Carr, Catherine J Wu, Kelly D Moynihan, Darrell J Irvine, David A Barbie, Ellis L Reinherz, Claudia Voena, Mark M Awad, Rafael B Blasco, Roberto Chiarle
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nature cancer (2023)
Elisa Bergaggio, Roberto Piva
Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. Cancers 11 (4) (2019)
Elisa Bergaggio, Chiara Riganti, Giulia Garaffo, Nicoletta Vitale, Elisabetta Mereu, Cecilia Bandini, Elisa Pellegrino, Verdiana Pullano, Paola Omedè, Katia Todoerti, Luciano Cascione, Valentina Audrito, Anna Riccio, Antonio Rossi, Francesco Bertoni, Silvia Deaglio, Antonio Palumbo, Roberto Piva
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood 133 (2) (2018)